PDS Biotechnology’s (PDSB) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a research note released on Wednesday morning, Benzinga reports. The firm currently has a $21.00 price objective on the stock. HC Wainwright also issued estimates for PDS Biotechnology’s Q1 2024 earnings at ($0.33) EPS, Q2 2024 earnings at ($0.31) EPS, Q3 2024 earnings at ($0.36) EPS, Q4 2024 earnings at ($0.39) EPS, FY2024 earnings at ($1.40) EPS, FY2025 earnings at ($1.58) EPS, FY2026 earnings at ($1.22) EPS, FY2027 earnings at ($1.15) EPS and FY2028 earnings at $0.33 EPS.

A number of other analysts have also weighed in on PDSB. StockNews.com lowered shares of PDS Biotechnology from a hold rating to a sell rating in a report on Saturday, March 16th. Cantor Fitzgerald reiterated an overweight rating on shares of PDS Biotechnology in a report on Friday, January 12th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, PDS Biotechnology presently has a consensus rating of Moderate Buy and a consensus price target of $17.33.

PDS Biotechnology Stock Performance

PDS Biotechnology stock opened at $3.96 on Wednesday. The company has a current ratio of 6.21, a quick ratio of 6.21 and a debt-to-equity ratio of 0.96. The firm has a 50-day moving average of $5.25 and a 200-day moving average of $5.09. The firm has a market cap of $123.20 million, a P/E ratio of -2.87 and a beta of 1.72. PDS Biotechnology has a 1-year low of $3.61 and a 1-year high of $10.27.

Institutional Investors Weigh In On PDS Biotechnology

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. EP Wealth Advisors LLC purchased a new stake in PDS Biotechnology in the third quarter worth approximately $52,000. Vontobel Holding Ltd. boosted its holdings in PDS Biotechnology by 28.1% in the third quarter. Vontobel Holding Ltd. now owns 41,000 shares of the company’s stock worth $207,000 after purchasing an additional 9,000 shares during the last quarter. Raymond James Financial Services Advisors Inc. purchased a new stake in PDS Biotechnology in the third quarter worth approximately $56,000. Corton Capital Inc. purchased a new stake in PDS Biotechnology in the third quarter worth approximately $112,000. Finally, Raymond James & Associates purchased a new position in shares of PDS Biotechnology during the 3rd quarter worth $123,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.